Hi-Tech Pharmacal Co., Inc. (NASDAQ:HITK) today reported results
for the third fiscal quarter ended January 31, 2014.
- Net sales of $59.9 million for the
third quarter compared to $64.3 million for the same prior year
period
- GAAP income of $8.4 million or $0.59
per diluted share for the third quarter
- Adjusted non-GAAP net income of $10.6
million or $0.75 per diluted share for the third quarter
- Net sales of $169.0 million for the
nine month period compared to $173.9 million for the same prior
year period
- GAAP income of $14.1 million or $1.00
per diluted share for the nine month period
- Adjusted non-GAAP net income of $28.3
million or $2.01 per diluted share for the nine month period
Three Months Ended January 31, Nine Months
Ended January 31, 2014 2013 2014
2013 Net sales $ 59,902,000 $ 64,331,000 $
169,004,000 $ 173,911,000 GAAP net income $ 8,351,000 $ 5,940,000 $
14,088,000 $ 20,868,000 Adjusted non-GAAP net income $ 10,605,000 $
8,512,000 $ 28,332,000 $ 28,252,000 GAAP Diluted EPS $ 0.59 $ 0.43
$ 1.00 $ 1.53 Adjusted non-GAAP Diluted EPS $ 0.75 $ 0.62 $ 2.01 $
2.08 Diluted Shares 14,220,000 13,730,000 14,100,000 13,603,000
(see Table I for reconciliation to GAAP
numbers)
Quarterly Results
For the three months ended January 31, 2014, the Company
reported net sales of $59,902,000, a decrease of 7% from
$64,331,000 for the same period last year.
During the quarter ended January 31, 2014, net sales of generic
pharmaceutical products were $47,761,000, a decrease of 12%
compared to $54,148,000 for the same fiscal 2013 period. The
primary reason for the decrease was due to lower sales of
Fluticasone Propionate nasal spray. Sales of Fluticasone decreased
to $10,900,000 from $23,000,000 in the same fiscal 2013 period as
the Company sold fewer units at a lower average price. Higher sales
of Guaiatussin AC, Lactulose, Clobetasol and sales of the newly
launched Bromfenac ophthalmic solution partially offset this
decrease.
Sales for the Health Care Products division (“HCP”), which
markets the Company’s branded OTC products, decreased 20% to
$4,106,000 for the three months ended January 31, 2014 compared to
$5,104,000 for the same fiscal period in the prior year due to
lower sales of Zostrix® and Sinus Buster®. Additionally, sales of
Diabetic Tussin® decreased due to a weaker cough, cold and flu
season.
Sales for ECR Pharmaceuticals (“ECR”), which markets the
Company’s branded prescription products, were $8,035,000 for the
three months ended January 31, 2014, up 58% from $5,079,000 for the
same period in the prior year. The increase was primarily due to a
price increase for TussiCaps®. In addition, sales of our Zolvit®
formula increased during the period after rebranding it as
Lortab®.
Cost of goods sold decreased to $27,962,000 for the three months
ended January 31, 2014 from $31,452,000, and decreased as a
percentage of sales to 47% from 49% of sales. The decrease in cost
of goods sold as a percentage of net sales is primarily due to
lower input costs and new manufacturing equipment that has enabled
productivity improvements. Additionally, the Company sold more
units of higher margin generic product and fewer units of lower
margin product. Price increases across most ECR product lines also
contributed to this trend.
Selling, general and administrative expenses decreased to
$14,212,000 from $16,538,000, a 14% decrease compared to the same
fiscal 2013 period. The decrease was partially due to decreases in
legal and accounting expenditures, and advertising for the HCP
division. As a percentage of sales, SG&A decreased to 24% from
26% for the three months ended January 31, 2014.
Amortization expense for the quarter ended January 31, 2014 was
$1,651,000, a slight increase from $1,618,000 for the comparable
fiscal 2013 period due to intangible asset purchases during the
fiscal year.
For the three months ended January 31, 2014, research and
product development costs decreased by 25% to $4,449,000 from
$5,964,000 for the comparable fiscal 2013 period due to the timing
of spending on projects requiring clinical trials.
For the three months ended January 31, 2014, the Company
recorded GAAP net income of $8,351,000, a 41% increase from net
income of $5,940,000, for the same period in the prior year. On a
fully diluted share basis, EPS increased 37% to $0.59 from $0.43 in
the prior year. The Company reported adjusted non-GAAP quarterly
net income of $10,605,000 or $0.75 per fully diluted share for the
three months ended January 31, 2014, compared to adjusted non-GAAP
net income of $8,512,000 or $0.62 per fully diluted share for the
same period in the prior year.
On August 26, 2013, the Company entered into a definitive
agreement under which Akorn, Inc. (“Akorn”) will acquire the
Company for cash. Under the terms of the agreement, Akorn will
acquire the Company for $640,000,000, or $43.50 per share. Akorn
intends to fund the transaction through a combination of Hi-Tech
cash assumed and approximately $600,000,000 in term loan
borrowings. The acquisition will be subject to customary
conditions, including termination of the waiting period under the
provisions of the Hart-Scott-Rodino Antitrust Improvements Act of
1976, as amended. Pending the satisfaction of such customary
conditions, the Company anticipates closing the transaction in
April of 2014.
Non-GAAP Financial Measures
The Company is disclosing non-GAAP financial measures when
providing financial results. Primarily due to settlements and loss
contingency accruals, the Company believes that an evaluation of
its ongoing operations (and comparisons of its current operations
with historical and future operations) would be difficult if the
disclosure of its financial results were limited to financial
measures prepared only in accordance with accounting principles
generally accepted in the U.S. (“GAAP”). In addition to disclosing
its financial results determined in accordance with GAAP, the
Company is disclosing certain non-GAAP results that exclude items
such as amortization and depreciation expense, share-based
compensation expense, interest expense and income, and other costs
related to settlements and loss contingency accruals in order to
supplement investors' and other readers' understanding and
assessment of the Company's financial performance, because the
Company's management uses these measures internally for
forecasting, budgeting and measuring its operating performance.
Whenever the Company uses such a non-GAAP measure, it will provide
a reconciliation of non-GAAP financial measures to the most closely
applicable GAAP financial measure. Investors and other readers are
encouraged to review the related GAAP financial measures and the
reconciliation of non-GAAP measures to their most closely
applicable GAAP measure set forth below and should consider
non-GAAP measures only as a supplement to, not as a substitute for
or as a superior measure to, measures of financial performance
prepared in accordance with GAAP.
Other Information
Hi-Tech is a specialty pharmaceutical company developing,
manufacturing and marketing generic and branded prescription and
OTC products. The Company specializes in difficult to manufacture
liquid and semi-solid dosage forms and produces a range of sterile
ophthalmic, otic and inhalation products. The Company’s Health Care
Products division is a leading developer and marketer of OTC
products for the diabetes marketplace. Hi-Tech’s ECR
Pharmaceuticals subsidiary markets branded prescription
products.
This press release contains certain future projections and
forward-looking statements (statements which are not historical
facts) with respect to the anticipated future performance of
Hi-Tech made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. Such future projections
and forward-looking statements are not assurances, promises or
guarantees and investors are cautioned that all future projections
and forward-looking statements involve significant business,
economic and competitive risks and uncertainties, many of which are
beyond Hi-Tech’s ability to control or estimate precisely;
including, but not limited to, (1) the impact of competitive
products and pricing, (2) product demand and market acceptance, (3)
new product development, (4) the regulatory environment, (5)
reliance on key strategic alliances, (6) availability of raw
materials, (7) fluctuations in operating results, (8) loss of
customers or employees, (9) the possibility that legal proceedings
may be instituted against Hi-Tech, (10) the occurrence of any
event, change or other circumstances that could give rise to the
termination of Hi-Tech’s merger agreement with Akorn, (11) the
failure to satisfy any of the other closing conditions to the
merger, (12) the failure of Akorn to obtain the necessary financing
arrangements set forth in the commitment letter providing for its
financing of the merger, (13) risks related to disruption of
management’s attention from Hi-Tech’s ongoing business operations
due to the transaction, (14) the effect of the announcement of the
merger on the ability of Hi-Tech to retain and hire key personnel
and maintain relationships with its customers, suppliers and others
with whom it does business, or on its operating results and
business generally, and (15) other results and other risks detailed
from time to time in Hi-Tech’s filings with the Securities and
Exchange Commission. The actual results will vary from the
projected results and such variations may be material. These
statements are based on management’s current expectations and
assumptions concerning the future performance of Hi-Tech and are
naturally subject to uncertainty and changes in circumstances. No
representations or warranties are made as to the accuracy or
completeness of any of the information contained herein, including,
but not limited to, any assumptions or projections contained herein
or forward-looking statements based thereon. We caution you not to
place undue reliance upon any such forward-looking statements which
speak only as of the date made, except to the extent specifically
dated as of an earlier date. Hi-Tech is under no obligation, and
expressly disclaims any such obligation, to update, alter or
correct any inaccuracies herein, whether as a result of new
information, future events or otherwise.
Three Months Ended January 31, Nine Months
Ended January 31, 2014 2013 2014
2013 Net sales $ 59,902,000 $ 64,331,000 $
169,004,000 $ 173,911,000 Cost of goods sold 27,962,000
31,452,000 80,329,000
86,122,000 Gross profit 31,940,000 32,879,000
88,675,000 87,789,000 Costs and expenses: Selling, general
and administrative expense 14,212,000 16,538,000 40,761,000
38,875,000 Amortization expense 1,651,000 1,618,000 4,960,000
5,136,000 Research and product development costs 4,449,000
5,964,000 13,499,000 13,779,000 Royalty income (243,000 ) (368,000
) (813,000 ) (1,403,000 ) Contract research income — — (554,000 )
(2,000 ) Settlements and loss contingencies — — 10,200,000 —
Interest expense 69,000 138,000 245,000 441,000 Interest income and
other (509,000 ) (60,000 ) (599,000 )
(183,000 ) Total $ 19,629,000 $ 23,830,000 $
67,699,000 $ 56,643,000 Income before
provision for income taxes 12,311,000 9,049,000 20,976,000
31,146,000 Provision for income tax expense 3,960,000
3,109,000 6,888,000 10,278,000
Net income $ 8,351,000 $ 5,940,000 $
14,088,000 $ 20,868,000 Basic earnings per
share $ 0.60 $ 0.44 $ 1.03 $ 1.58
Diluted earnings per share $ 0.59 $ 0.43 $
1.00 $ 1.53
Weighted average common shares
outstanding,basic
13,863,000 13,409,000 13,694,000 13,216,000 Effect of potential
common shares 357,000 321,000
406,000 387,000
Weighted average common shares
outstanding,diluted
14,220,000 13,730,000 14,100,000
13,603,000
Table I
Hi-Tech Pharmacal Co., Inc.
Reconciliation of Non-GAAP
Measures
Three Months Ended January 31, 2014
2013 GAAP
Non-GAAPAdjustments
Non-GAAPAs Adjusted
GAAP
Non-GAAPAdjustments
Non-GAAPAs Adjusted
Net sales $ 59,902,000 $ — $ 59,902,000 $ 64,331,000 $ — $
64,331,000 Cost of goods sold 27,962,000
113,000(a ) 27,849,000 31,452,000
125,000(a ) 31,327,000 Gross profit
31,940,000 (113,000 ) 32,053,000 32,879,000 (125,000 ) 33,004,000
Costs and expenses:
Selling, general
andadministrativeexpense
13,069,000 794,000(a ) 12,275,000 15,525,000 923,000(a ) 14,602,000
Amortization expense 1,651,000 1,651,000(b ) — 1,618,000
1,618,000(b ) — Depreciation expense 1,143,000 1,143,000(c ) —
1,013,000 1,013,000(c ) —
Research and productdevelopment costs
4,449,000 234,000(a ) 4,215,000 5,964,000 231,000(a ) 5,733,000
Royalty income (243,000 ) — (243,000 ) (368,000 ) — (368,000 )
Interest expense 69,000 69,000(e ) — 138,000 138,000(e ) —
Interest income andother
(509,000 ) (509,000 )(f) —
(60,000 ) (60,000 )(f) — Total $
19,629,000 $ 3,382,000 $ 16,247,000 $
23,830,000 $ 3,863,000 $ 19,967,000
Income (loss) beforeprovision for
incometaxes
12,311,000 (3,495,000 ) 15,806,000 9,049,000 (3,988,000 )
13,037,000
Provision for incometax expense
(benefit)
3,960,000 (1,241,000 )(g) 5,201,000
3,109,000 (1,416,000 )(g)
4,525,000 Net income (loss) $ 8,351,000 $
(2,254,000 ) $ 10,605,000 $ 5,940,000 $ (2,572,000 )
$ 8,512,000
Basic earnings pershare
$ 0.60 $ 0.76 $ 0.44 $ 0.63
Diluted earnings pershare
$ 0.59 $ 0.75 $ 0.43 $ 0.62
Weighted averagecommon sharesoutstanding,
basic
13,863,000
13,863,000 13,409,000 13,409,000
Effect of potentialcommon shares
357,000 357,000 321,000
321,000
Weighted averagecommon sharesoutstanding,
diluted
14,220,000 14,220,000 13,730,000
13,730,000
Nine Months Ended
January 31, 2014 2013 GAAP
Non-GAAPAdjustments
Non-GAAPAs Adjusted
GAAP
Non-GAAPAdjustments
Non-GAAPAs Adjusted
Net sales $ 169,004,000 $ — $ 169,004,000 $ 173,911,000 $ — $
173,911,000 Cost of goods sold 80,329,000
395,000(a ) 79,934,000 86,122,000
342,000(a ) 85,780,000 Gross profit
88,675,000 (395,000 ) 89,070,000 87,789,000 (342,000 ) 88,131,000
Costs and expenses:
Selling, general
andadministrativeexpense
37,319,000 2,708,000(a ) 34,611,000 35,926,000 2,194,000(a )
33,732,000 Amortization expense 4,960,000 4,960,000(b ) — 5,136,000
5,136,000(b ) — Depreciation expense 3,442,000 3,442,000(c ) —
2,949,000 2,949,000(c ) —
Research and productdevelopment costs
13,499,000 733,000(a ) 12,766,000 13,779,000 569,000(a ) 13,210,000
Royalty income (813,000 ) — (813,000 ) (1,403,000 ) — (1,403,000 )
Contract researchincome
(554,000 ) — (554,000 ) (2,000 ) — (2,000 )
Settlements and losscontingencies
10,200,000 10,200,000(d ) — — — — Interest expense 245,000
245,000(e ) — 441,000 441,000(e ) —
Interest income andother
(599,000 ) (599,000 )(f) —
(183,000 ) (183,000 )(f) — Total $
67,699,000 $ 21,689,000 $ 46,010,000 $
56,643,000 $ 11,106,000 $ 45,537,000
Income (loss) beforeprovision for
incometaxes
20,976,000 (22,084,000 ) 43,060,000 31,146,000 (11,448,000 )
42,594,000
Provision for incometax expense
(benefit)
6,888,000 (7,840,000 )(g) 14,728,000
10,278,000 (4,064,000 )(g)
14,342,000 Net income (loss) $ 14,088,000 $
(14,244,000 ) $ 28,332,000 $ 20,868,000 $ (7,384,000
) $ 28,252,000
Basic earnings pershare
$ 1.03 $ 2.07 $ 1.58 $ 2.14
Diluted earnings pershare
$ 1.00 $ 2.01 $ 1.53 $ 2.08
Weighted averagecommon sharesoutstanding,
basic
13,694,000 13,694,000 13,216,000 13,216,000
Effect of potentialcommon shares
406,000 406,000 387,000
387,000
Weighted averagecommon sharesoutstanding,
diluted
14,100,000 14,100,000 13,603,000
13,603,000 (a) Share-based
compensation expense (b) Amortization expense (c) Depreciation
expense (d) Net charge related to settlements and loss
contingencies (e) Interest expense (f) Interest income and other
(g) Total tax effect for non-GAAP pre-tax adjustments measured at
enacted statutory rates
Hi-Tech Pharmacal Co., Inc.William Peters, 631-789-8228CFO
Hi Tech (NASDAQ:HITK)
Historical Stock Chart
From Apr 2024 to May 2024
Hi Tech (NASDAQ:HITK)
Historical Stock Chart
From May 2023 to May 2024